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INTRODUCTION
Upper gastrointestinal tract includes the oesophagus, stomach and 
duodenum. Patients with diseases of upper gastrointestinal system generally 
present with symptoms of dysphagia, abdominal pain, vomiting and hematemesis.
Upper gastrointestinal (GI) endoscopy is a diagnostic procedure that 
visualizes the upper part of the gastrointestinal tract upto the duodenum. It is an 
established mode of investigation and treatment of wide range of upper 
gastrointestinal conditions. It has replaced upper GI radiography as the primary 
method of diagnosing upper GI illness.
Helicobacter pylori (H.pylori) is a spiral shaped organism associated with 
gastrointestinal disease in humans. It causes a chronic gastric infection that usually 
is life long and many epidemiologic studies have shown that this is probably one of 
the most common bacterial infection throughout the world, involving 40% to 50% 
of the population in developed countries and 80% to 90% of the population in 
developing regions.88 Over 80% of individuals infected with this bacterium are 
asymptomatic.
It causes a chronic low-level inflammation of the stomach. The clinical outcomes 
associated with H.pylori infection include duodenal ulcer, gastric ulcer, gastric 
adenocarcinoma and gastric mucosa-associated lymphoid tissue (MALT) lymphoma. 
The bacterium has been classified as a class I definite gastric carcinogen to human.42
H.pylori infection can be diagnosed by invasive (i.e., requiring endoscopy) 
and non-invasive techniques (i.e., techniques that do not require endoscopy with 
biopsy sampling).54
Eradication of H.pylori improved markedly the inflammatory cell infiltration 
characteristic of H.pylori related gastritis, inhibited recurrence of peptic ulcer68 and also 
led to regression of MALT lymphoma.59
In this study the various methods of identification of H.pylori and the 
histopahological features associated with H.pylori in the gastric mucosa in patients 
presenting with dyspepsia are discussed.
AIM OF THE STUDY
To  study  the  incidence  of  various  lesions  in  the  upper 
gastrointestinal biopsy materials received.
To  estimate  the  magnitude  of  Helicobacter  pylori  infection  among  dyspeptic 
patients.
To study the efficacy of invasive and non-invasive methods to detect Helicobacter 
pylori infection.
To find out the etiological association between Helicobacter pylori  and peptic 
ulcer.
REVIEW OF LITERATURE
EMBRYOLOGY
The  epithelial  lining  of  the  various  parts  of  gastrointestinal  tract  is  that  of 
endodermal origin.
Stomach
The stomach is first seen as a fusiform dilatation of the foregut just distal to the 
oesophagus. Its distal border is attached to the posterior abdominal wall by a fold of 
peritoneum  called  the  dorsal  mesogastrium.  Its  ventral  border  is  attached  to  the 
septum transversum by another fold of peritoneum called the ventral mesogastrium.
The stomach undergoes differential growth resulting in a considerable change 
in the shape and orientation. The original ventral border comes to face upward and to 
the right and becomes the lesser curvature. The dorsal border now points downwards 
and to the left and becomes greater curvature. The original left surface becomes its 
anterior surface and the original right surface becomes the posterior surface.
ANATOMY OF STOMACH
The stomach extends from just  left  of  the midline where it  is  joined to the 
oesophagus, to just right of the midline where it is connected to the duodenum. It 
resembles a large gland.
The concavity of the right, the inner curve is called the lesser curvature, and the 
convexity of the left, outer curve is the greater curvature. An angle along the lesser 
curve,  the  incisura  angularis,  marks  the  approximate  point  at  which  the  stomach 
narrow prior to its junction with the duodenum.  The most distal and narrow portion 
of the stomach is termed the pylorus.
In the empty state, the stomach is contracted and its mucosa and submucosa are 
thrown up into distinct folds called rugae; when distended with food, the rugae are 
"ironed out" and flat. It secretes a complex of digestive enzymes, acid and mucus.
The stomach is divided into 5 anatomic regions (Fig. 1)
1. Cardia  -  Narrow  conical  portion  of  the  stomach  immediately  distal  to  the 
gastroesophageal junction.
2. Fundus  -  Dome-shaped  portion  of  the  proximal  stomach  that  extends 
superolateral to the gastroesophageal junction.
3. Body or  Corpus - Comprises the remainder of  the stomach proximal  to the 
incisura angularis.
4. Antrum - The stomach distal to the incisura angularis.
5. Pylorus - The most distal and narrow portion of the stomach.
HISTOLOGY OF STOMACH
The gastric wall consists of mucosa, submucosa, muscularis propria and serosa.
Mucosa
It has two compartments. The superficial foveolar compartment and the deep 
glandular compartment.
Foveolar compartment
It consists of surface epithelial cells lining the entire mucosal surface as well as 
gastric pits.
It is relatively uniform throughout the stomach. The surface epithelium shows a 
regular  picket-fence  arrangement,  with a  plentiful  diffuse  secretion  of  mucus.  All 
foveolar  cells  secrete  mucus,  in  contrast  to  the  scattered  goblet  cells  between 
absorptive cells lining the intestine. The cells are tall, with regular basal nuclei. The 
epithelial surface appears flat on light microscopy. This epithelium lines a system of 
pits (foveolae).
In the body of the stomach, the pits are short tubules, with long, closely packed 
glands opening into them (Fig 7).  When seen in three dimensions,  the pits in the 
antrum have a partial cerebriform structure of complex folds. They extend about a 
third the way through the antral  mucosa.  Mucus-secreting glands branch from the 
base of these pits   (Fig 8). The superficial parts of the glands form narrow straight 
tubules, the gland necks, lined by epithelium similar to the outer surface but with 
smaller cells.
A primary function of the foveolar cells is the secretion of mucus. A dense 
layer of mucus globules fills the superficial one to two thirds of the cells. Normal 
foveolar mucus consists mainly of neutral glycoprotein, which is strongly periodic 
acid - Schiff (PAS) positive and stain weakly with alcian blue. Intestinal mucins stain 
strongly with alcian blue.
A combination of alcian blue and PAS [alcian-PAS] shows these differences 
practically  well.  Foveolar  mucus  stains  a  rich  magenta  red.  In  contrast,  intestinal 
mucus stains a variety of purple and indigo blue colors as a result of the presence of 
acidic glycoproteins.
One notable exception is the secretion of Brunner’s glands in the duodenum, 
which  stains  a  brighter  red  than  the  gastric  foveolar  mucus.  Brunner’s  glands, 
however, are deep to the muscularis mucosae and are irregular and glandular in form, 
in contrast to foveolae.
Glandular Compartment
It  exhibits  major  difference  in  thickness  and  in  glandular  composition  in 
different  regions  of  stomach.  It  consists  of  gastric  glands,  which  vary  between 
anatomic regions.
1. Cardiac glands contain mucus secreting cells only.
2. Oxyntic glands (also called gastric / fundic glands) found in the fundus and 
body and contain parietal cells, chief cells and scattered endocrine cells.
3. Antral or pyloric glands contain mucin secreting cells and endocrine cells.
The normal gastric mucosa shows another unusual feature. It is the only part of 
the gastrointestinal tract with almost no lymphoid tissue.
HELICOBACTER PYLORI
Before the first  isolation and documentation of Helicobacter pylori from the 
human  stomach  in  1982,  it  was  assumed  that  the  human  stomach  was  a  sterile 
environment because of the high levels of acid, which would exclude it as an ecologic 
niche for any organism.
H.pylori was introduced into the scientific community in 1982. Marshall51 
and Warren90 described a campylobacter-like bacterium that was seen in large 
numbers in the gastric mucus of patients with chronic gastritis and duodenal 
ulcers.
HISTORICAL PERSPECTIVE
German  scientists  found  spiral-shaped  bacteria  in  the  lining  of  the  human 
stomach in 1875, but they were unable to culture it and the results were eventually 
forgotten.9
Professor  Walery  Jaworski45 of  the  Jagiellonian  University  in  Krakow 
investigated sediments of gastric washings obtained from humans in  1899. Among 
some rod-like bacteria, he also found bacteria with a characteristic spiral shape, which 
he called Vibrio rugula. He was the first to suggest a possible role of this organism in 
the pathogenesis  of  gastric  diseases.  This  work was included in  the Handbook of 
Gastric Diseases, but it had little impact as it was written in Polish.
Several small studies conducted in the early 1900s demonstrated the presence 
of  curved  rods  in  the  stomach  of  many  patients  with  peptic  ulcers  and  stomach 
cancer.26
The  interest  waned  when  an  American  study  published  in  1954  failed  to 
observe the bacteria in 1180 stomach biopsies.62
However the role of bacteria in stomach diseases was rekindled in the 1970s 
with the visualization of bacteria in the stomach of gastric ulcer patients.78
The bacterium had also been observed in 1979 by Australian pathologist Robin 
Warren,  who did  further  research  on  it  with  Australian  physician  Barry  Marshall 
beginning in 1981.  After numerous unsuccessful  attempts at culturing the bacteria 
from the stomach, they finally succeeded in visualizing colonies in 1982 when they 
unintentionally left their Petri dishes incubating for 5 days over the Easter weekend.
In  their  original  paper,  Warren  and  Marshall  contended  that  most  stomach 
ulcers and gastritis were caused by infection by this bacterium and not by stress or 
spicy food as had been assumed before.53
Although there was some skepticism initially, within several years, numerous 
research  groups  verified  the  association  of  H.pylori  with  gastritis  and  to  a  lesser 
extent ulcers.3
To demonstrate the role of H.pylori with gastritis, Marshall drank a beaker of 
H.pylori. He became ill several days later with nausea and vomiting. An endoscopy 
performed ten days after inoculation revealed signs of gastritis and the presence of 
H.pylori. These results suggested that H.pylori was the causative agent of gastritis.
Marshall  and  Warren  also  showed  that  antibiotics  were  effective  in  the 
treatment of many cases of gastritis.
In 1987 the Sydney gastroenterologist Thomas Borody14 invented the first triple 
therapy for the treatment of duodenal ulcers.
In 1994, the National Institute of Health (USA) published an opinion stating 
that  most  recurrent  duodenal  and  gastric  ulcers  were  caused  by  H.pylori  and 
recommended  antibiotics  in  the  treatment  regimen.38 Warren  and  Marshall  were 
awarded the Nobel Prize in Medicine in 2005 for their wonderful work on H.pylori.83
EPIDEMIOLOGY
At least half the world's population is infected by H.pylori making it the most 
widespread infection in the world.53 Actual infection rates vary from nation to nation. 
The Third World has much higher infection rates than the West (Western Europe, 
North America, Australia), where the rates are estimated to be around 25%.66
Infections are usually acquired in early childhood in all countries.46 However, 
the infection rate of children in developing nations is higher than in industrialized 
nations, probably due to poor sanitary conditions.
In developed nations it is currently uncommon to find infected children. The 
percentage of infected people increases with age, 50% infected are over the age of 60 
compared with 10% between 18 and 30 years of age.66 The higher prevalence among 
the elderly reflects the fact that they were infected from childhood.46
Prevalence appears to be higher in African-American and Hispanic populations, 
although this  is  likely  related  to  socioeconomic  rather  than  racial  factors.76,27 The 
lower rate of infection in the West is largely attributed to higher hygiene standards 
and widespread use of antibiotics. Despite high rates of infection in certain areas of 
the  world,  the  overall  frequency  of  H.pylori  infection  is  declining.48 However, 
antibiotic  resistance  is  appearing  in  H.pylori  and  many  metronidazole  and 
clarithromycin resistant strains seen in most parts of the world.55
H.pylori  is  contagious,  although  the  exact  route  of  transmission  is  not 
known.56,17 Person-to-person transmission by either the oral-oral or fecal-oral route is 
most  likely.16 Consistent  with  these  transmission  routes,  the  bacteria  have  been 
isolated from feces, saliva and dental plaque of some infected people.16
Transmission occurs mainly within families in developed nations yet can also 
be  acquired  from the  community  in  developing countries.22  H.pylori  may  also  be 
transmitted orally by means of fecal  matter  through the ingestion of waste-tainted 
water.  Hence  a  hygienic  environment  could  help  to  decrease  the  risk  of  H.pylori 
infection.16
MORPHOLOGY
H.pylori  is  a  spiral  to  curved,  rod  shaped,  gram  negative  microaerophilic 
bacterium about 3 microns long with a diameter of about 0.5 micron. It has 4 to 7 
polar  sheathed  flagella,  which  enable  the  bacterium  to  move  freely  in  viscous 
environments such as gastric mucus.37
This bacterium is the human-adapted helicobacter primarily found in the gastric 
mucosa and areas of gastric metaplasia in the duodenum and occasionally in Meckel’s 
diverticulum and rectum.20,58
BIOCHEMICAL CHARACTERISTICS
H.pylori is urease, catalase and oxidase positive. The urease activity is striking, 
and  the  amounts  produced  have  allowed  accurate  diagnosis  in  patients  by  direct 
detection of the enzyme in gastric biopsy specimens and by breath tests using carbon 
isotopes labelled with urea.
Many  roles  have  been  proposed  for  urease  enzyme.  It  is  known to  be 
important  for  colonization  and  survival  of  the  bacterium  in  the  gastric 
environment.25
The hydrolysis of urea to ammonia by urease could have a buffering effect, 
protecting the bacterium from acidity.49
In  vitro  studies  have  shown  that  helicobacter  pylori  cannot  survive  in 
acidic condition without the presence of urea,  and urea inhibits its growth in 
alkaline  conditions.19,57,70 Urease  also  has  been  proposed  as  an  important 
virulence factor.
GENETICS
In  1997,  the  complete  genomic  sequence  of  Helicobacter  pylori  strain 
26695  was  published.84 This  bacterium has  a  single  circular  chromosome  of 
1,667,867  base  pairs  and  1590  predicated  coding  sequence  of  which  1091 
matched database sequence of  genes are known from other organisms.
PATHOPHYSIOLOGY
To colonize the stomach H.pylori must survive in the acidic pH of the lumen 
and burrow into the mucus to reach its niche, close to the stomach's epithelial cell 
layer. The bacterium has flagella and moves through the stomach lumen and drills 
into the mucoid lining of the stomach.60
Many bacteria can be found deep in the mucus, which are continuously secreted 
by mucous cells and removed on the luminal side. To avoid being carried into the 
lumen, H.pylori senses the pH gradient within the mucus layer by chemotaxis and 
swims away  from the  acidic  contents  of  the  lumen  towards  the  more  neutral  pH 
environment of the epithelial cell surface.71
H.pylori is also found on the inner surface of the stomach epithelial cells and 
occasionally inside epithelial cells.65  It produces adhesins which bind to membrane-
associated lipids and carbohydrates  and help it  adhere to epithelial  cells.  Adhesin 
BabA binds to the Lewis b antigen displayed on the surface of stomach epithelial 
cells.41
H.pylori produces large amounts of the enzyme urease, molecules of which are 
localized inside and outside of the bacterium. Urease breaks down urea (which is 
normally  secreted  into  the  stomach)  to  carbon  dioxide  and  ammonia  (which 
neutralizes gastric acid). The survival of H.pylori in the acidic stomach is dependent 
on urease,  and it  would eventually  die  without the enzyme.  The ammonia that  is 
produced and other products of H.pylori such as protease, vacuolating cytotoxin A 
(VacA), and certain phospholipases are toxic to the epithelial cells.77
Colonization  of  the  stomach  by  H.pylori  results  in  chronic  gastritis.  The 
severity of the inflammation is likely to underlie H.pylori related diseases.74 Duodenal 
and stomach ulcers result when the consequences of inflammation allow the acid and 
pepsin in the stomach lumen to overwhelm the mechanisms that protect the stomach 
and duodenal mucosa from these caustic substances.
The type of ulcer that develops depends on the location of chronic gastritis, 
which occurs at the site of H.pylori colonization.24   The acidity within the stomach 
lumen affects the colonization pattern of H.pylori and therefore ultimately determines 
whether a duodenal or gastric ulcer will form.
In people producing large amounts of acid, H.pylori colonizes the antrum of the 
stomach to avoid the acid-secreting parietal cells located in the corpus (main body) of 
the  stomach.46 The  inflammatory  response  to  the  bacteria  induces  G  (gastrin-
producing) cells in the antrum to secrete the hormone gastrin, which travels through 
the bloodstream to the corpus.10 Gastrin stimulates the parietal cells in the corpus to 
secrete even more acid into the stomach lumen. Chronically increased gastrin levels 
eventually cause the increase in the number of parietal cells, further escalating the 
amount  of  acid  secreted.72 The  increased  acid  load  damages  the  duodenum  and 
ulceration may eventually result.
In contrast, gastric ulcers are often associated with normal or reduced gastric 
acid production, suggesting that the mechanisms that protect the gastric mucosa are 
defective.72 In these patients H.pylori can also colonize the corpus of the stomach, 
where the acid-secreting parietal cells are located. However, chronic inflammation 
induced by the bacteria causes further reduction of acid production and eventually, 
atrophy of the stomach lining, which may lead to gastric ulcer and increases the risk 
for stomach cancer.80
About  50-70%  of  H.  pylori  strains  in  Western  countries  carry  the  Cag 
pathogenicity island (Cag PAI).63  Western patients infected with strains carrying the 
Cag (cytotoxin-associated antigen) PAI have a stronger inflammatory response in the 
stomach and are at a greater risk of developing peptic ulcers or stomach cancer than 
those infected with strains lacking the island.46  Following attachment of H.pylori to 
stomach  epithelial  cells,  the  type  IV secretion  system expressed  by  the  Cag  PAI 
"injects" the inflammatory inducing agent peptidoglycan from their own cell wall into 
the  epithelial  cells.  The  injected  peptidoglycan  is  recognized  by  the  cytoplasmic 
immune sensor Nod1, which then stimulates expression of cytokines that  promote 
inflammation.88
The type IV secretion apparatus also injects the Cag PAI-encoded protein CagA 
into the stomach's epithelial cells,  where it  disrupts the cytoskeleton, adherence to 
adjacent cells, intracellular signaling, and other cellular activities.4 Once inside the 
cell the CagA protein is phosphorylated on tyrosine residues by a host cell membrane-
associated tyrosine kinase.
Pathogenic  strains  of  H.pylori  have  been  shown  to  activate  the  epidermal 
growth factor receptor (EGFR), a membrane protein with a tyrosine kinase domain. 
Activation of the EGFR by H.pylori is associated with altered signal transduction and 
gene expression in host epithelial cells that may contribute to pathogenesis. It has also 
been suggested that a c-terminal region of the CagA protein (amino acids 873-1002) 
can  regulate  host  cell  gene  transcription  independent  of  protein  tyrosine 
phosphorylation.5,15
Two related mechanisms by which H.pylori could promote cancer are under 
investigation. One mechanism involves the enhanced production of free radicals near 
H.pylori and an increased rate of host cell mutation. The other proposed mechanism 
has  been  called  a  "perigenetic  pathway"86 and  involves  enhancement  of  the 
transformed  host  cell  phenotype  by  means  of  alterations  in  cell  proteins  such  as 
adhesion  proteins.  It  has  been  proposed  that  H.pylori  induces  inflammation  and 
locally high levels of TNF-α (tumor necrosis factor- α) and/or IL-6 (interleukin-6). 
According to the proposed perigenetic mechanism, inflammation-associated signaling 
molecules such as TNF-α can alter gastric epithelial cell  adhesion and lead to the 
dispersion and migration of mutated epithelial cells without the need for additional 
mutations  in  tumor  suppressor  genes  such  as  genes  that  code  for  cell  adhesion 
proteins.81
H.pylori  colonizes the stomach and induces chronic gastritis.  The bacterium 
persists  in  the  stomach for  decades  in  most  people.  Most  individuals  infected  by 
H.pylori  will  never  experience clinical  symptoms despite  having chronic  gastritis. 
Approximately 10-20% of those colonized by H.pylori will ultimately develop gastric 
and duodenal ulcers.46 H.pylori infection is also associated with a 1-2% lifetime risk 
of stomach cancer and a less than 1% risk of gastric MALT lymphoma.46
It is widely believed that in the absence of treatment, H.pylori infection-once 
established in its gastric niche-persists for life.60 In the elderly, however, it is likely 
that infection can disappear as the stomach's mucosa becomes increasingly atrophic 
and inhospitable to colonization. The proportion of acute infections that persist is not 
known,  but  several  studies  that  followed  the  natural  history  in  populations  have 
reported apparent spontaneous elimination.33,32
While  H.pylori  has  been  disappearing  from  the  stomach  of  humans,  the 
incidence  of  the  related  disorders  acid  reflux  disease,  Barrett's  esophagus,  and 
esophageal cancer have been rising dramatically.9
In 1996, Martin J. Blaser advanced the hypothesis that H.pylori has a beneficial 
effect:  by  regulating  the  acidity  of  the  stomach contents,  it  lowers  the  impact  of 
regurgitation of gastric acid into the esophagus.9,10 The hypothesis is not universally 
accepted as several randomized controlled trials failed to demonstrate worsening of 
acid reflux disease symptoms following eradication of H.pylori.36,21
Nevertheless, Blaser has refined his view to assert that H.pylori is a member of 
the normal flora of the stomach.86 He postulates that the changes in gastric physiology 
caused by the loss of H.pylori account for the recent increase in incidence of several 
diseases, including type 2 diabetes, obesity, and asthma.13,11 His group has recently 
shown that H.pylori colonization is associated with a lower incidence of childhood 
asthma.18
CLINICAL OUTCOMES ASSOCIATED WITH H.PYLORI
Peptic ulcer (Fig. 3,4)
H.pylori associate strongly with duodenal ulcers, than with gastric ulcers.53 
Gastric  metaplasia  of  the  duodenal  mucosa  is  common  in  places  near  the 
duodenal ulcers.
Carcinoma
There  is  a  growing  body  of  evidence  that  H.pylori  is  a  precursor  of 
carcinoma of the body and antrum of the stomach.42,29,47 H.pylori infection causes 
chronic gastritis and it leads to development and progression of atrophic gastritis 
and  intestinal  metaplasia,  which  are  considered  precursor  lesions  of  gastric 
cancer.  Some  strains  of  H.pylori  may  be  more  carcinogenic  than  others, 
especially CagA-positive bacteria.12
MALT Lymphoma
Primary Non-Hodgkin Lymphoma (NHL) of the stomach is a relatively rare 
malignant disorder, accounting for about 5% of gastric tumors. The cause of primary 
gastric NHL had been unknown because by definition NHLs are malignant clonal 
diseases of the lymphatic tissue, and the stomach is a site that is normally considered 
to be devoid of organized lymphoid tissue.23,43,64
The  association  between  Mucosa  associated  lymphoid  tissue  (MALT) 
lymphoma and H.pylori was postulated for the first time in 1998 with the recognition 
that  the  cause  of  acquired  gastric  MALT  is  chronic  infection  with  H.pylori.79,93 
Wother-spoon et al92  were the first to investigate the presence of H.pylori in larger 
numbers  of  gastric  lymphomas  of  the  MALT  type  (MALToma).  H.pylori  was 
detected in 92% of cases.
They suggested that H.pylori (and Helicobacter heilmannii) might trigger the 
acquisition of MALT in the gastric mucosa, and this lymphoid tissue is thought to 
harbor the precursor cells for MALT NHL. These precursor cells changes gradually 
into  malignant  lymphoma  cells  with  autonomous  and  uncontrolled  growth  by 
accumulation  of  genetic  alteration,  mutations,  deletions  and  amplifications  (i.e., 
trisomy 3 and 7).
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The  active  changes  defined  by  Whitehead  et  al91  are  linked  closely  with 
H.pylori  infection  in  humans.  These  changes,  together  with  non-specific  chronic 
gastritis, usually accompany helicobacter infection.
Three features make the diagnosis:
1. The presence of uniform small curved bacilli, closely adherent to the surface of 
the epithelium
2. A  typical  infiltration  of  the  epithelium  by  polymorphonuclear  neutrophil 
leukocytes (neutrophils)
3. The typical epithelial distortion, which is specific but often absent.
Identification and distribution of organism
The bacteria play an important part in the histopathology of H.pylori gastritis. 
Small  numbers  of  H.pylori  may  still  be  difficult  to  find.  A  search  with  the  oil 
immersion lens usually  reveals  any organisms.  Single  Helicobacter-like organisms 
can  be  recognized.  [Small,  pale,  curved,  well-formed  bacilli].  Immunoperoxidase 
antibodies  are  also  available.  Polymerase  chain  reaction  provides  a  sensitive  and 
specific method of identification.
H.pylori show marked variation in number and distribution. They proliferate 
mostly  on  the  superficial  foveolar  epithelium.  Fewer  bacilli  grow  in  the  gastric 
mucosal pits.
Occasional Helicobacter organism grow in the inflamed gland necks but almost 
never in the glands. They tend to adhere closely to the surface of the epithelial cells, 
particularly in the antrum, often palisading. Unattached bacilli  are commonly seen 
deep in the mucus.
The H.pylori is of unusual length in occasional biopsy specimens. They may be 
less than half or almost double the usual length. In most well-fixed specimens, they 
are small, pale, curved bacilli and remarkably constant in appearance. Single bacillus 
is easy to identify with oil immersion microscopy.
H.heilmannii is larger and more tightly coiled. They tend to infiltrate into the 
glands,  often  in  the  fundus,  and produce  remarkably  little  reaction.  In  contrast  to 
H.heilmannii, H.pylori is rare in the actual corpus mucosa gastric glands (as distinct 
from the necks of the glands).
Foreign bacteria are common on gastric biopsy specimens. They show variation 
in size than H.pylori,  which are larger  with darker  staining than others.  They are 
usually seen above the mucus secretion but not on the epithelial cell surface.
H.pylori grow well on intact antral mucosa and also in the fundus, usually in 
smaller  numbers  than  in  the  antrum.  When  the  fundal  mucosa  is  intact,  the 
Helicobacter organisms seen less firmly attached to the epithelial surface. They often 
float deep in the mucus layer.
H.pylori grow only on gastric-type epithelium, and a dense proliferation of the 
bacteria stops within one cell of a focus of mature intestinal metaplasia.
Sometimes few bacteria grow on areas of partial or atypical metaplasia, with 
PAS-positive mucus in the epithelial cells between the goblet cells.
They  sometimes  grow on the  areas  of  gastric  metaplasia  in  the  duodenum, 
usually patchy and fewer in number than the antrum. Infected areas often show active 
inflammation, similar to the stomach.
The  bacteria  rarely  grow  in  the  oesophagus  but  can  do  so  in  Barrett’s 
esophagitis with well-formed gastric metaplasia near the gastroesophageal junction.
Neutrophil infiltration (Fig. 11)
The features described by Whitehead et al91 as active gastritis almost always are 
associated with H.pylori infection.
H.pylori and epithelial  neutrophils show an almost  absolute correlation. The 
neutrophils infiltrate with a typical pattern, not seen otherwise. They usually infiltrate 
the epithelium of the necks of the glands, adjacent to the base of gastric mucosal pits. 
As  a  rule,  this  infiltration  is  most  obvious  in  the  gastric  antrum.  The  typical 
infiltration is focal.
Superficial epithelial neutrophils, without involvement of the gland necks, are 
less specific for H.pylori infection. The severity of the changes is of less diagnostic 
importance. These changes are related to the presence but not the number of H.pylori.
Neutrophils infiltrating the stroma (the mucosal lamina propria) are not clearly 
related to H.pylori infection. Neutrophils infiltrate into the lumen of some gland necks 
and may fill  the  overlying pits.  It  results  in microabscesses,  resembling the crypt 
abscesses of Ulcerative colitis or Crohn’s disease.
Specific epithelial changes
Normally  epithelial  cells  look rigid,  with  a  picket-fence  arrangement,  a  flat 
surface, regular small round basal nuclei, and plentiful superficial mucus secretion. 
The  main  specific  change  in  the  foveolar  epithelium is  a  disorganization  of  the 
structure of the epithelial cells. This may be mild, moderate, or severe and diffuse, 
patchy, or focal.
The  mildest  recognizable  specific  change  consists  of  a  definite  cobblestone 
irregularity of the epithelial surface. The surface is no longer flat; the cells bulge out.
When the changes are severe, the epithelial cells show ameboid features. The 
cells  lose  their  picket-fence  arrangement  and  the  basal  nuclear  polarization.  The 
epithelium often appears thickened, with irregular nuclei scattered throughout.
Microcrypts
Microcrypts, small spaces or virtual spaces within the foveolar epithelium, are 
often seen with H.pylori. Adjacent epithelial cells form a microcrypts by turning in on 
each other, producing an apparent intra-epithelial mucus-secreting gland.
Microcrypts are not specific for Helicobacter, but only infected mucosa shows 
them easily. Small groups of the bacteria often fill the microcrypts. One of the last 
places where the bacteria collect is in the microcrypts.
Mucus secretion
Factors that alter cell function tend to reduce secretion. Such factors include 
epithelial  proliferation,  inflammatory  damage,  atrophy  and  cellular  atypia  or 
dysplasia.  Reduced mucus secretion by the foveolar cells is observed with H.pylori 
infection.  The  gastritis,  rather  than  the  Helicobacter  may  cause  this  change.  The 
reduced mucus secretion could be a combination of direct bacterial  effect  and the 
associated inflammatory damage.
Reduced  mucus  secretion  with  a  diffuse  cobblestone  change  gives  an 
appearance resembling a string of beads [PAS stain]. These changes are well seen in 
the antrum.
Nonspecific changes:
1. Epithelial changes
(i). Atrophy (Fig. 12)
Helicobacter infiltration and the changes of active gastritis are most obvious in 
the gastric antrum. The appearance of atrophy in the antrum is deceptive, however. 
Atrophy is easier to recognize in the corpus, where it is mild, focal or absent.
The glands become separated, with increasing loss of chief and parietal cells. 
The inflammatory infiltration is mild and superficial.  The most severe cases show 
widespread intestinal metaplasia. In such areas, Helicobacter is sparse or absent, and 
the stromal inflammation decreases.
(ii). Metaplasia (Fig. 13,14)
Metaplasia indicates a change in the gastric epithelium to resemble the lining of 
the small intestine [intestinal metaplasia]. The basic histologic structure of the gastric 
mucosa remains intact. Metaplastic changes are mainly seen in the superficial part of 
the epithelium. When metaplasia extends into the glands, they usually show marked 
distortion and atrophy, but they do not resemble intestinal crypts,  which are much 
shorter and more regular.
The metaplastic epithelium can show a wide range of appearances. In type I 
intestinal  metaplasia,  the  metaplastic  epithelium  resemble  mature  small  intestinal 
epithelium.  In  type  II  metaplasia,  the  epithelium  frequently  undergoes  a  partial, 
incomplete, or atypical metaplastic changes. This metaplasia may consists of scattered 
goblet  cells  in  regular  epithelium  showing  a  variable  amount  of  gastric  mucus 
secretion.   In  type  III  metaplasia,  foveolar-like  cells  are  large  with  nuclear 
irregularity, poor mucus secretion and poorly formed goblet cells.
There is marked difference between the superficial epithelium of the stomach 
and the intestine. Gastric foveolar epithelium secretes neutral glycoproteins diffusely 
from  all  cells.  The  intestine  secretes  acidic  mucins  from  scattered  goblet  cells, 
separated by nonsecretory cells. A standard H&E stain shows the goblet cells and 
microvilli, but small foci of metaplasia are easy to miss. Specific stains for mucus 
give a much more sensitive and definite result.  Alcian-PAS provides an excellent 
method of finding metaplasia quickly and easily in the stomach or duodenum.
The relationship between Helicobacter and metaplasia is complex. H.pylori do 
not  grow on intestinal  epithelium, including intestinal  metaplasia.  Because of  this 
fact,  larger  areas  of  mature  intestinal  metaplasia  in  the  stomach  show  reduced 
inflammation, with regular epithelium and no active changes.
2. Stromal changes
H.pylori  causes  nonspecific  inflammation  of  the  mucosal  stroma  (lamina 
propria). This inflammation varies considerably and usually is most obvious in the 
antrum (Fig.9). The most striking change is an infiltration of lymphoid cells, which 
are  almost  absent  in  the normal  stomach.  Often a  moderate  diffuse infiltration of 
lymphocytes  extends  through  the  full  thickness  of  the  mucosa  to  the  muscularis 
mucosae.
Other less  common patterns of  lymphocytic  infiltration include fine diffuse, 
superficial,  patchy or  focal  and dense  diffuse.  Small  follicle-like  concentration  of 
lymphocytes are frequent (Fig.10). Fully developed lymphoid follicles, with germinal 
centers, are uncommon.
Congestion and edema are common. Patchy fibrosis accompanies more severe 
damage, often related to varying degree of glandular distortion and atrophy. Other 
cells often present in small numbers include eosinophils and mast cells.
Electron microscopy
The normal gastric epithelium consists of a sheet of well-formed cylindric cells. 
The superficial surface is flat, with numerous microvilli.  The microvilli are not as 
numerous or well formed as those on the intestinal cells, but they still are plentiful 
and fairly regular.  Fibrils attach into the microvilli,  extend through the cytoplasm, 
past the globules of mucus and the nucleus, and into the base of the cell. These fibrils 
appear to provide a skeleton that maintains the cell shape and internal structure, with a 
flat surface.
With H.pylori infection, the bacteria attach to the epithelial cells, with patches 
resembling cell junction. They often attach to the microvilli. The microvilli become 
distorted, thickened, and reduced in number. As the microvilli disappear, the fibrils 
also disappear.  The cells  lose their  skeleton and become somewhat  ameboid.  The 
intercellular junctions and basal junction may weaken, but they remain intact and hold 
the cell  in  position.  The cell  surface  bulges out,  however,  giving the cobblestone 
appearance often seen with H.pylori infection.
Changes after treatment
Patients with mild pathology reverted to normal within two weeks of treatment. 
The neutrophil infiltration and the active changes in the epithelium vanished with the 
bacteria.  The  foveolar  epithelium  soon  returned  to  normal,  with  normal  mucus 
secretion and regular  picket-fence appearance.  The lymphoid infiltration improved 
slowly.  It  was  usually  mild  after  twelve months  and normal,  almost  absent,  after 
seven years.30
DIAGNOSIS
H.pylori infection can be diagnosed by invasive (i.e., requiring endoscopy) and 
noninvasive techniques (i.e., techniques that do not require endoscopy). Each of the 
available diagnostic techniques has advantages and disadvantages.
Non-invasive techniques
1. Serologic testing
2. Urea breath tests
3. Stool tests
Invasive techniques
1. Urease tests
2. Biopsy
3. Culture
4. Polymerase chain reaction
Serologic testing 
This  is  the  commonest  method  of  non-invasive  diagnosis  for  H.pylori. 
Generally  the  prevalence  of  raised  IgG  in  the  population  tends  to  be  higher  in 
developing  countries  than  in  developed  countries.  Soon  after  the  discovery  of 
H.pylori, Jones et al44 described a complement fixation test that had an accuracy of 
80% to 90%. Alternative methods,  such as hemagglutination,  were available soon 
after  this50,  followed  by  more  sophisticated  enzyme-linked  immunosorbent  assay 
(ELISA) methods, such as those first described by Good-win et al.34
The various serodiagnostic techniques used in detecting H.pylori are Bacterial 
agglutination44,  Complement  fixation  test,  Haem-agglutination,  ELISA,  Western 
blotting,  Co-agglutination,  Immuno-fluorescence,  Radio-immunoassay  and  Latex 
agglutination.
Sensitivity  and  specificity  of  ELISA  depend  largely  on  the  nature  of  the 
antigenic materials bound to the solid support.39,82 Although more expensive, the gold 
standard for a serologic test is an immunoblot, in which a visual representation of 
multiple antigens can be obtained in an individual patient.
In cases in which serologic response has been studied, it appears to be similar 
to any other bacterial infection (i.e., after approximately 14 days, IgM is present and 
by 21days, IgG is detectable). IgM declines over the next 3 months so that patients 
with chronic H.pylori infection usually have no IgM but always have IgG. IgA is 
variable. The antibody titres preserve their levels even after the eradication of the 
bacteria by antibacterial therapy. A 50% fall in titer of IgG between 6 and 9 months 
after treatment is predicted as cure.
Urea breath tests
This test is based on organism’s urease activity, which liberates carbon dioxide 
(CO2) from urea and produces ammonia to buffer its acidic environment. Ingestion of 
labeled urea results in the production of labeled CO2, which then can be detected in 
the breath. In contrast to antibody based testing, the urea breath test identifies patients 
with active H.pylori infection.
Two forms of labeled urea are available: one contains the stable, nonradioactive 
isotopes  13C, and the other  contains the radioactive isotope  14C. Because of  broad 
exposure of ingested  14C-urea to the gastric mucosa, sampling error theoretically is 
less of  a problem with the urea breath test  than with the biopsy based diagnostic 
methods for H.pylori.
Stool tests
Culture of H.pylori has been obtained from stool samples, but viable organisms 
are  present  only in  a  small  percentage of  cases.  An enzymatic  immunoassay that 
detects the presence of H.pylori antigen in stool specimen is also available. The test 
uses polyclonal  anti-H.pylori capture antibody absorbed to microwells.  The HpSA 
(Helicobacter pylori Stool Antigen) test has received approval from the US Food and 
Drug  Administration  for  two  indications:  Diagnosis  of  H.pylori  infection  in 
symptomatic adults and monitoring response, post therapy in adults.
Urease test
With the observation that H.pylori was a strong urease producer, several groups 
began to work on the use of urease as a marker for H.pylori in the human stomach. 
This work ultimately resulted in the rapid urease test and the urea breath test, both are 
now widely used in the diagnosis of this common infection.
The enzyme was active at physiologic temperatures, with an optimum of 450C. 
The enzyme was found to be rapidly denatured in acid, so that it was inactive at any 
pH less than 4.5. Active urease is located only beneath the mucus layer where the pH 
is neutral and the H.pylori organism resides. Urease tests can be based on biopsy or 
can  be  performed  on  samples  of  gastric  mucus  scraped  and  retrieved  from  the 
stomach at endoscopy.
False  positive  results  may  occur  when  non-H.pylori  helicobacter  organisms 
infect  the  gastric  mucosa.  Helicobacter  heilmannii  is  also  urease  positive.  Urease 
reactions  are  less  intense  with  non-H.pylori  helicobacter  organisms  and  are  more 
likely to be positive in the corpus rather than in the antral mucosa.
Patients  taking  omeprazole  often  have  achlorhydria.  With  subsequent 
superficial colonization of the gastric mucus layer with urease producing organisms 
(e.g., Proteus mirabilis or Klebsiella) can give a false-positive urease test after 24 hrs 
of inoculation but generally are negative when the test is read 1 hour after biopsy 
insertion.
The presence of achlorhydria causes false-negative urease test results because 
the luminal pH of 7.0 can lead to an extremely high pH adjacent to the organism such 
that H.pylori is destroyed by the action of its own urease.
Biopsy
The bacteria are an important part of the histopathology of H.pylori gastritis. 
Bacterial  stains  for  histology  must  contrast  the  organisms  against  the  complex 
background of a tissue section. The position of H.pylori on the surface of mucus-
secreting cells, makes histological staining a little easier. The method must stain the 
organism and not the mucus.
Commonly  used  special  stains  include  Warthin-Starry,  Giemsa,  Diff-Quik, 
Genta and El-Zimaity’s triple stain. The Warthin-Starry method stains the bacteria 
black and shows them well. A simplified version of the Giemsa stain works well. The 
stain,  should  be  heated  for  a  short  time.  One should  adjust  the  time to  stain  the 
Helicobacter and not the mucus, using a positive control slide. This method destroys 
the color balance expected with Giemsa but not required for bacteria. The bacteria 
stain blue with a white or pale blue background.
The contrast between the bacteria and background tissue is greatest with the 
Genta stain. In contrast, gastric morphology is better with El-Zimaity’s triple stain. 
The  Diff-Quik,  an  inexpensive  histologic  stain,  has  excellent  sensitivity  and 
specificity.
For the detection of  scant number of  organisms,  immunohistochemistry 
proved  to  be  highly  specific  and  sensitive  and  superior  to  conventional 
histochemical methods.6,85
IHC for detection of H.pylori in gastric biopsies has also been shown to 
improve  the  rate  of  identification  of  the  organisms  after  treatment  when 
histologic examination and cultures were negative.
Polymerase chain reaction
The application of polymerase chain reaction (PCR) with respect to H.pylori is 
useful for molecular epidemiologic aspects as well as for detection purposes. PCR can 
be used  to  distinguish between strains of  H.pylori  and in  typing and determining 
reinfections.8 Current detection methods by PCR are aimed at detecting H.pylori in 
clinical samples collected by less invasive means, such as gastric juice, saliva, dental 
plaque, and faeces.
TREATMENT75
Cure of H.pylori infection is not easy and requires combinations of antibiotics 
often with additional non-antibiotic adjunctive agents.
Recommended regimens to treat H.pylori infection
Bismuth triple therapy
Bismuth two tablets four times daily
Metronidazole 250mg four times daily
Tetracyclin 500mg four times daily
Proton pump inhibitor (PPI) triple therapy
PPI twice daily
Amoxicillin 1000mg twice daily
Clarithromycin 500mg twice daily (or)
Metronidazole 500mg twice daily
Quadruple therapy
PPI twice daily
Bismuth two tablets three or four times daily.
Metronidazole 500mg three or four times daily.
Tetracyclin 500mg three or four times daily.
The most effective regimens to cure H.pylori infection are combinations of two 
antibiotics and adjunctive agents taken for 14 days.
The most  effective  and best  tolerated  combination  seems to  be twice-a-day 
combination of 1000mg of amoxicillin and 500mg of clarithromycin  [PPI + AC] or 
500mg of metronidazole and either 250 or 500mg of clarithromycin [PPI + MC].
Quadruple therapy
The  triple  therapy  is  often  sufficient  unless  the  organism  being  treated  is 
resistant  to  clarithromycin  or  metronidazole.  One  regimen  that  provides  effective 
eradication of H.pylori in either instance is high dose quadruple therapy.
Definition of cure
It is defined as absence of the organism by tests performed no sooner than four 
weeks after cessation of antimicrobial therapy.
MATERIAL AND METHODS
The present study was carried out in the Department of Pathology, Madurai 
Medical College, Madurai for a period of two years from August 2007 to July 2009.
During this two year study period, 105 gastric biopsy materials and 105 serum 
samples  were  collected  for  Helicobacter  pylori  study  in  patients  presenting  with 
dyspepsia.
Patients were clinically diagnosed as suffering from dyspepsia based on the 
following symptoms: nausea, vomiting, anorexia, heartburn, flatulence, regurgitation, 
early satiety, fullness and bloating in addition to pain or discomfort.90 The working 
proforma is appended in annexure I.
We received a total of 414 biopsy materials from different levels of the upper 
gastrointestinal tract. The biopsy materials were obtained by using flexible fibreoptic 
upper gastrointestinal endoscope. Specimens were collected from the Department of 
Medical Gastroenterology, Government Rajaji Hospital, Madurai.
Study design - Prospective study.
Inclusion criteria:-
Patients of both sex above 12 years of age who were found to have peptic ulcer, 
gastritis, duodenitis and normal on endoscopy on evaluation of dyspepsia were taken 
up for the study.
Exclusion criteria:-
1. History of antibiotic ingestion in the previous 4 to 6 weeks.
2. History of ingestion of antacids or H2 blockers or proton pump inhibitors and 
Non-steroidal anti-inflammatory drugs over the past 4 to 6 weeks.
Methodology
Informed consent was obtained from all patients included in this study. The 
relevant history and clinical details were recorded using a structured proforma.
After  overnight  fasting,  oesophagogastroduodenoscopy  was  done  on  the 
following morning. Three gastric biopsy materials,  one from corpus and two from 
antrum of stomach were obtained. One antral specimen was used for urease test in the 
endoscopic room itself. Remaining biopsy materials were used for histopahological 
examination.  2ml  blood  was  collected  by  venipuncture  for  IgG  ELISA  serology 
investigation.
Detection of Helicobacter pylori
Rapid Urease Test
One gastric antral biopsy specimen was taken and placed immediately in 5ml of 
freshly prepared solution of 10% urea containing 1% phenol red as pH indicator. 
Change of colour from yellow to pink was observed in the next 24 hrs.
Histopathological examination
Two gastric  biopsy  materials  from corpus and antrum of  the  stomach were 
taken for histopahological examination and fixed in 10% neutral buffered formalin. 
The tissues were processed, paraffin blocked, 5 microns thin sections were cut and 
stained with Hematoxylin and Eosin (H&E) and Giemsa stains. H&E staining was 
used  for  the  histological  diagnosis  of  activity  of  H.pylori  infection,  mucosal 
inflammation, glandular atrophy and intestinal metaplasia. Giemsa staining was used 
for the histological diagnosis of H.pylori infection.
Being active was signified by the presence of neutrophils within the glandular 
and surface epithelial layer. Glandular atrophy was identified when the gastric glands 
were correspondingly decreased in amount and/or widely separated.
An increase in lymphocytes and plasma cells in lamina propria categorizes the 
gastritis as chronic. As an arbitrary guideline, infiltration involving upto 1/3 of the 
gastric pits and surface are designated mild; between 1/3 and 2/3 moderate and more 
than  this  as  severe 67.  Lymphoid  aggregates  were  defined  as  accumulation  of 
lymphocytes without germinal center formation.61,40
Serologic testing
Collected  blood  by  venipuncture  was  allowed  to  clot  and  the  serum  was 
separated by centrifugation at a speed of 3000 rpm for 5 min at room temperature. 
The serum samples were stored at -200C. Using DEMEDITEC H.pylori IgG antibody 
ELISA test kit, detection and quantitative determination of specific IgG antibodies 
against H.pylori in serum was done.
The information collected was recorded in  a  master  chart.  The results  were 
compared.  ‘P’  value  analysis  was  used  for  statistical  calculation  to  arrive  at  the 
conclusion.
Sensitivity,  specificity  and  accuracy  were  calculated  using  the  following 
formulae and taking histopahological findings as the gold standard.
Screening test 
results
Diseased Not Diseased
Positive True Positive (TP) False Positive (FP)
Negative False Negative (FN) True Negative (TN)
Sensitivity = TP / (TP + FN) x 100
Specificity = TN / (FP + TN) x 100
Accuracy = TP + TN / (TP + FP + FN + TN) x 100
OBSERVATION AND RESULTS
Biopsy  materials  were  obtained  from  different  levels  of  the  upper 
gastrointestinal tract in 414 patients including 144 biopsies from the oesophagus, 42 
from oesophagogastric junction, 222 from stomach and 6 from small intestine.
In  the  oesophagus,  136  biopsies  showed  malignancy,  4  biopsies  showed 
oesophagitis and 4 biopsies were inadequate for histopahological examination. In the 
stomach,  1  inflammatory  polyp,  95  malignancies,  1  foreign  body  granuloma,  20 
inadequate  specimens,  15  normal  gastric  mucosa  and  90  specimens  with  varying 
grades of gastritis were noted.
273  biopsy  materials  showed  malignant  lesions  that  were  located  in  the 
oesophagus (in 136 patients), stomach (in 95 patients) and oesophagogastric junction 
(in 42 patients). Squamous cell carcinoma was noted in 136 biopsies obtained from 
oesophagus  and  17  biopsies  from  oesophagogastric  junction.  Adenocarcinoma 
comprises 95 biopsies of stomach and 25 biopsies of oesophagogastric junction. In the 
small intestine 1 villous atrophy and 5 normal mucosa were noted [Table 1 and Chart 
1].
Among  the  patients  with  oesophageal  malignancy,  dysphagia  was  the  most 
common presenting symptom. Dyspepsia  and weight  loss  were the most  common 
symptoms of gastric malignancy.
Table 1:  Incidence of various lesions of upper gastrointestinal biopsy materials
Location Inadequate 
material
Normal 
mucosa
Inflammed 
mucosa
Polyp Granuloma Villous 
Atrophy
Malignancy
Oesophagus 4 - 4 - - - 136
OG junction - - - - - - 42
Stomach 20 15 90 1 1 - 95
Small 
Intestine
- 5 - - - 1 -
Chart 1: Incidence of various lesions of upper gastrointestinal biopsy materials
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In the present study, a total of 105 Gastric biopsy materials were studied for the 
detection of H.pylori and the various histopahological features observed in dyspeptic 
patients.
As per the proforma, the clinical data was collected from the patients who had 
undergone the upper gastrointestinal endoscopic procedure. After studying the biopsy 
and serum samples following observation were documented.
Sex distribution of all cases
Out of the total 105 cases, 69 (65.7%) cases were males and 36 (34.3%) cases 
were females [Table 2 and Chart 2].
Table 2: Sex distribution of all cases
Chart 2: Sex distribution of all cases
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Sex distribution of positive cases
Out of 69 males, 54 (56.3%) males were positive for H.pylori and out of 36 
females, 20 (55.6%) females were positive for H.pylori [Table 3 and Chart 3].
Table 3: Sex distribution of positive cases
S.no Sex No of cases Positive cases Percentage
1. Male 69 54 56.3
2. Female 36 20 55.6
Chart 3: Sex distribution of positive cases
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Age distribution of all cases
In the present study, the age group of patients ranged from 17 years to 82 years 
and the maximum numbers of cases were found in the age group of 31- 40 years, 
comprising a total of 31.4% of the study population.
The least number of cases were in the age groups of 13-20 and above 70 years, 
each comprising a total of 1.9% of the study population.
Among females, no cases were found in the age groups of 13-20 years and above 70 
years.
The youngest patient among males was 17 year old and the oldest patient was 
82 year old.
The youngest patient among females was 26 year old and the oldest patient was 
70 year old [Table 4 and Chart 4].
Table 4: Age distribution of all cases
S.no Age group 
(yrs)
No of cases
Male Female
Total Percentage
1. 13 - 20 2 - 2 1.9
2. 21 - 30 8 7 15 14.3
3. 31 - 40 22 11 33 31.4
4. 41 - 50 13 8 21 20
5. 51 - 60 10 7 17 16.2
6. 61 - 70 12 3 15 14.3
7. Above 70 2 - 2 1.9
Total 69 36 105 100
Chart 4: Age distribution of all cases
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Age distribution of positive cases
Maximum numbers of positive cases were found in the age group of 51-60 
years (88.2%).
Minimum numbers of  positive cases were found in  the age group of  13-20 
years (50%) [Table 5 and Chart 5].
Table 5: Age distribution of positive cases
Age group No of cases Positive cases Percentage
13 - 20 2 1 50
21- 30 15 10 66.7
31- 40 33 22 66.7
41- 50 21 16 76.2
51- 60 17 15 88.2
>60 17 10 58.8
Chart 5: Age distribution of positive cases
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Endoscopic findings
Out  of  the  105  cases,  54  cases  had  normal  mucosa  (Fig.2),  30  cases  had 
duodenal  ulcer,  9 cases had gastric ulcer,  8 cases had duodenitis and 4 cases had 
gastritis.
Endoscopic findings of positive cases
Out  of  39  peptic  ulcer  cases  (30  duodenal  ulcer  and  9  gastric  ulcer),  35 
(89.74%) cases [28 (93%) duodenal and 7 (77.8%) gastric ulcer] showed H.pylori 
positivity. Among 66 non-ulcer cases (8 duodenitis, 4 gastritis and 54 normal mucosal 
appearance on endoscopy) 39 cases [6 duodenitis (75%), 3 (75%) gastritis and 30 
(55.6) normal mucosal appearance on endoscopy] showed H.pylori positivity [Table 6 
and Chart 6].
Table 6: Endoscopic findings
S.no Endoscopic 
findings
No of 
cases
Positive 
cases
Percentage
1. Normal mucosa 54 30 55.6
2. Duodenal ulcer 30 28 93
3. Gastric ulcer 9 7 77.8
4. Duodenitis 8 6 75
5. Gastritis 4 3 75
Chart 6: Endoscopic findings
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Rapid urease test
Out of 105 patients, 86 [81.9%] patients were positive for H.pylori by rapid 
urease test.  The pink to red color development represents a positive test (Fig. 5,6) 
[Table 7 and Chart 7].
Table 7: Rapid urease test (RUT)
S.no No of cases Positive cases Percentage
1. 105 86 81.9
Chart 7: Rapid urease test (RUT)
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Serological assay
Out of the 105 cases, 90 [85.7%] cases were positive for H.pylori by serological 
method. The observed cut-off value was 0.516. And the value of the sample higher 
than that of cut-off value was considered positive indicated by development of yellow 
color. (Fig.18) [Table 8 and Chart 8].
Table 8: Serological assay
S.no No of cases Positive cases Percentage
1. 105 90 85.7
Chart 8: Serological assay
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Histopathology
Using Giemsa stain, the spiral shaped bacteria of H.pylori stained blue, were 
found attached to the brush border of the gastric foveolar epithelial cells and inside 
gastric pits (Fig.15,16). 
Out  of  the  105  cases,  74  (70.5%)  cases  were  positive  for  H.pylori  by 
histopahological examination.
There  were  74  positive  H.pylori  cases  in  the  study  group  (70.5%)  and  31 
negative subjects (29.5%). 56.3% of males and 55.6% of females in the study group 
were positive for H.pylori [Table 9 and Chart 9].
Table 9: Histopathology
S.no No of cases Positive cases Percentage
1. 105 74 70.5
Chart 9: Histopathology
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Histopathological features
Histopathologically,  60  cases  (57.1%)  showed  evidence  of  chronic  active 
gastritis,  of  which  58  cases  (96.7%)  were  H.pylori  positive.  Mild  gastritis  was 
evidenced in 13 cases (12.4%), of which 10 cases (76.7%) were H.pylori positive. 15 
cases were normal (14.3%) of which 5 cases (33.3%) were H.pylori positive. Ten 
cases of intestinal metaplasia (9.5%) and two cases of atrophy (1.9%) were detected, 
all were H.pylori negative. Five cases of dysplasia (4.8%) (Fig.17) were found, of 
which one case (20%) was H.pylori positive (Fig.14). Lymphocyte infiltration was 
more prominent in the antrum [Table 10 and Chart 10].
Table 10: Histopathological features
S.no Histopathological 
features
No of 
cases
Positive 
cases
Percentage
1. Chronic active gastritis 60 58 96.7
2. Normal gastric mucosa 15 5 33.3
3. Mild chronic gastritis 13 10 76.7
4. Intestinal metaplasia 10 - -
5. Chronic gastritis with 
dysplastic glands
5 1 20
6. Chronic atrophic gastritis 2 - -
Chart 10: Histopathological features      
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Correlation of Rapid urease test, Histopathological and Serological methods
Out of 86 positive cases in rapid urease test, only 69 cases showed H.pylori by 
Giemsa staining.
Out of 90 positive cases in serological assay, only 73 cases showed H.pylori by 
Giemsa staining [Table 11 and Chart 11].
Table  11: Correlation  of  Rapid  urease  test,  Histopathological  and  Serological 
methods
S.no Tests No of Cases Positive Cases
1. Rapid urease test 105 86
2. Histopathology 105 74
3. Serological assay 105 90
Chart  11: Correlation  of  Rapid  urease  test,  Histopathological  and  Serological 
methods
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DISCUSSION
The most impressive advance has come from the flexible fibroscope with which 
it is possible to examine the oesophagus, stomach and duodenum and at the same time 
obtain biopsies for histopahological examination.
Infection with Helicobacter pylori is a world-wide chronic infection with the 
highest  incidence  in  developing  countries.  It  is  associated  with  duodenal  ulcer, 
chronic  active  gastritis,  gastric  cancer  and  gastric  lymphoma.  It  can  be  easily 
identified on biopsy specimens taken at endoscopy.
Chronic gastritis is defined as the presence of chronic mucosal inflammatory 
changes leading eventually to mucosal atrophy and epithelial metaplasia. By far the 
most  important  aetiological  association  is  chronic  infection  by  the  bacillus 
Helicobacter  pylori.  The  organism  is  a  worldwide  pathogen  that  has  the  highest 
infection rates in developing countries.
Sex distribution
In the present study, out of 69 males, 54 (56.3%) males and out of 36 females, 
20 (55.6%) females are positive for H.pylori. The male to female ratio is 1:1 which is 
comparable to a study by Abdur Rauf Khan1. He studied a total of 528 biopsies. There 
are  313 males,  among whom 217 males  (69%) are  positive  for  H.pylori  and 215 
females, among whom 136 females (63%) positive for H.pylori. The male to female 
ratio is 1:1.
Age distribution
The higher prevalence of H.pylori is in the age group of 51-60 years (88.2%).
Endoscopic features
Normal looking gastric mucosa is the commonest single endoscopic finding, 
accounting for 51.4% of all cases.
The positivity rate for duodenal ulcer is 93% and gastric ulcer is 77.8% in our 
study. It is comparable to a study by Tytget87 [1988] who found that all 15 (100%) 
patients of duodenal ulcer and 9 out of 11 (81.8%) patients with gastric ulcer found to 
have the organism. And in 2002, Sengupta et al73 studied antral biopsy specimens 
from 25 patients with symptoms and diagnosis of duodenal ulcer, amongst whom the 
positivity rate is 84%.  In a study by Zhang C, Yamada N et al94, the prevalence of 
H.pylori in gastric ulcer is 80.8%.
Duodenal  ulcer  is  usually  associated  with  H.pylori  infection.  Treatment  of 
duodenal ulcer must therefore include acid reduction and H.pylori eradication all the 
time.
Rapid urease test (RUT) and Serological assay
In the present study, H.pylori is positive in 86 (81.9%) cases by RUT and in 90 
(85.7%) cases by serological assay. It correlates with a study done by U Arora et al2. 
They studied 75 gastric biopsy specimens and 75 serum samples of same patients 
complaining of dyspepsia. H.pylori is positive in 52 cases (72%) by RUT and in 57 
cases (76%) by serological testing. Gill et al31 have shown that antibodies to H.pylori 
in  serum are  present  in  about  80% of  Indian  subjects  with  upper  gastrointestinal 
symptoms. In our study also the positivity rate is 85.7% which is very well correlated 
with the previous mentioned study.
Some of those methods are based on the high urease activity of H.pylori,52,35 but 
because they detect all enzyme activity of urease regardless of its origin, there is the 
possibility that urease derived from other bacterial species, such as Proteus mirabilis 
or Klebsiella pnuemoniae, will confound the result.
Serological identification of anti-H.pylori antibodies is a non-invasive method. 
However, the antibody titres preserve their levels even after the eradication of the 
bacteria by antibacterial therapy.
Histopathology
The prevalence of H.pylori in the present study is 70.5%. It is similar to a study 
by  Abdul Rahman E Fakhro et al28 and  a study by Basic H, Katic V et al7. In their 
study the prevalence rates are 79.4% and 71.8% respectively.
Histopathologically, 60 cases out of 105 patients (57.1%) showed evidence of 
chronic active gastritis, of which 58 cases (96.7%) are H.pylori positive. Mild gastritis 
is evidenced in 13 cases (12.4%), of which 10 cases (76.7%) are H.pylori positive. 15 
cases are normal (14.3%) of which 4 cases (26.7%) are H.pylori positive. Ten cases of 
intestinal  metaplasia (9.5%) and two cases of atrophy (1.9%) are detected,  all  are 
H.pylori  negative.  Five  cases  of  dysplasia  (4.8%)  are  found,  of  which  two cases 
(40%) are H. pylori positive.
Abdul  Rahman  E  Fakhro  et  al28 studied  102  gastric  biopsies  in  dyspeptic 
patients.  In their  study, 66 cases out of 102 patients (64.7%) showed evidence of 
chronic active gastritis, of which 65 cases (98.5%) are H.pylori positive. Mild gastritis 
is evidenced in 15 cases (14.7%), of which 9 cases (60%) are H.pylori positive. 16 
cases are normal, of which 3 cases (18.8%) are H.pylori positive. Our study results 
are comparable to this study.
SUMMARY
A total of 414 upper gastrointestinal biopsy materials are received.
It includes 273 malignant lesions, 20 normal and 94 inflammed mucosa, 24 
inadequate materials, 1 inflammatory polyp, 1 foreign body granuloma and 1 villous 
atrophy.
In the present study, 105 gastric biopsy materials and 105 serum samples are studied 
for the detection of H.pylori in patients presenting with dyspepsia.
Out of the 105 cases, 86 [81.9%] cases are positive for H.pylori by rapid urease test 
and 74 (70.5%) cases by histopahological examination.
The maximum numbers of positive cases (90 cases) are diagnosed by serological 
assay.
Men and women are equally affected by H.pylori infection.
Histopathological examination is the gold standard test for H.pylori detection against 
which the sensitivity, specificity and accuracy of serologic testing are 98.65%, 
45.16% and 82.86% respectively.
The sensitivity, specificity and accuracy of rapid urease test are 93.24%, 45.16% and 
79.05% respectively.
In cases of intestinal metaplasia and atrophic gastritis, there are no demonstrable 
H.pylori organisms.
Among the 105 cases, 39 cases had peptic ulcer (30 duodenal ulcer and 9 gastric 
ulcer)
The H.pylori positivity rate for peptic ulcer is 89.74% (duodenal ulcer is 93% and 
gastric ulcer is 77.8%).
CONCLUSION
To conclude H.pylori infection affects both genders equally. The sensitivity, 
specificity  and  accuracy  of  serologic  testing  are  98.65%,  45.16%  and  82.86% 
respectively.  Serological identification of anti-H.pylori antibodies is a non-invasive 
method. However, the antibody titres preserve their levels even after the eradication 
of the bacteria by antibacterial therapy. The sensitivity, specificity and accuracy of 
rapid urease test are 93.24%, 45.16% and 79.05% respectively. Methods based on the 
high urease activity of H. pylori detect all enzyme activity of urease regardless of its 
origin, there is the possibility that urease derived from other bacterial species, such as 
Proteus  mirabilis or  Klebsiella  pnuemoniae,  will  confound the result.  Presence  of 
H.pylori is strongly associated with the occurrence of peptic ulcer (P < 0.001).

ANNEXURE I
PROFORMA
S.No:
NAME: AGE: SEX:
ADDRESS: UNIT: WARD:
OP / IP No:
COMPLAINTS:
1. Upper abdominal pain
2. Abdominal discomfort
3. Bloating sensation
4. Early satiety
5. Post prandial fullness
6. Heartburn
ALARM SYMPTOMS:
1. Dysphagia
2. Upper GI bleed (hematemesis / melena)
3. Persistent vomiting
4. Sensation of an abdominal mass
5. Jaundice
6. Loss of weight
7. Loss of appetite
PAST HISTORY:
Systemic illness
Drug intake: (Antibiotics / PPI / Metronidazole)
PERSONAL HISTORY:
Alcohol intake
Smoking
Betel chewing
EXAMINATION:
Nutritional status
Anemia
Jaundice
Abdomen: Epigastric tenderness
Abdominal mass
CLINICAL DIAGNOSIS:
INVESTIGATIONS:
1. Blood urea
2. Serum creatinine
3. Hemoglobin
4. Erythrocyte sedimentation rate (ESR)
5. Ultrasonography of abdomen
6. Upper GI endoscopy
7. Rapid urease test
8. Biopsy findings
9. Stains for Helicobacter pylori
FINAL DIAGNOSIS:
ANNEXURE II
H & E STAIN
1. Sections to water.
2. Stain with Ehrlich’s hematoxylin solution for 30 minutes.
3. Wash briefly in water and differentiate in 1% acid alcohol.
4. Wash well in water and blue for 10 to 30 seconds.
5. Wash in water and stain with 1% eosin solution for 30 seconds to 
1minute.
6. Wash quickly in water, differentiate and dehydrate in alcohol. Clear 
and mount.
GIEMSA STAIN
1. Bring sections down to water through graded alcohols
2. Rinse in pH 6.8 buffered distilled water
3. Stain in working Giemsa stain, overnight
4. Rinse in distilled water
5. Rinse in 0.5% aqueous acetic acid until section is pink
6. Wash in tap water
7. Blot until almost dry
8. Dehydrate rapidly
Results:
Organism - dark blue
Back ground - pink to pale blue
SEROLOGIC TESTING
Principle of the test
The DEMEDITEC H.pylori  IgG antibody test  kit  is  based on the 
principle of the enzyme immunoassay (EIA). Helicobacter antigen is bound 
on the surface of the microtiter strips. Diluted serum is pipetted into the 
wells of the microtiter plate. A binding between the IgG antibodies of the 
serum and the immobilized Helicobacter antigen takes place. After an hour 
of incubation at room temperature, the plate is rinsed with diluted wash 
solution,  in  order  to  remove  unbound  material.  Then  anti-human-IgG 
peroxidase  conjugate  is  added  and  incubated  for  30  minutes.  After 
washing, the substrate solution is pipetted and incubated for 20 minutes, 
inducing  the  development  of  a  blue  dye  in  the  wells.  The  color 
development  is  terminated  by  the  addition  of  a  stop  solution,  which 
changes  the  color  from blue  to  yellow.  The  resulting  dye  is  measured 
spectrophotometrically at the wavelength of 450nm. The concentration of 
the IgG antibodies is directly proportional to the intensity of the color.
Assay steps
1. Bring all reagents and samples to room temperature.
2. Prepare  a  sufficient  amount  of  microtiter  wells  for  the  standards, 
controls and samples in duplicate as well as for a substrate blank.
3. Dilute the serum samples with sample diluent in a ratio of 1:101 (e.g. 
5uL serum + 500 uL sample diluent).
4. Pipet  100  uL  each  of  the  diluted  (1:101)  samples,  standards  and 
controls into the wells. Leave one well empty for the substrate blank.
5. Cover  plate  with  the  enclosed  foil  and  incubate  at  370C  for  60 
minutes.
6. Empty the wells of the plate (dump or aspirate) and add 300uL of 
diluted  washing  solution.  This  procedure  is  repeated  totally  three 
times. Rests of the washing buffer are afterwards removed by gentle 
tapping of the microtiter plate on a tissue cloth.
7. Pipet 100 uL of conjugate into the wells. Leave one well empty for 
the substrate blank.
8. Cover  plate  with  the  enclosed  foil  and  incubate  at  370C for  30 
minutes.
9. Empty the wells of the plate (dump or aspirate) and add 300uL of 
diluted  washing  solution.  This  procedure  is  repeated  totally  three 
times. Rests of the washing buffer are afterwards removed by gentle 
tapping of the microtiter plate on a tissue cloth.
10.Pipet  100uL  of  the  substrate  into  the  wells.  This  time  also  the 
substrate blank is pipetted.
11.Incubate without covering at room temperature for 20 minutes in the 
dark.
12.To terminate the substrate reaction, pipet 100uL of stop solution into 
the wells. Pipet also the substrate blank.
13.After thorough mixing and wiping the bottom of the plate, perform 
the  reading  of  the  absorption  at  450  nm  (optionally  reference 
wavelength of 620 nm).
14.The mean values for the measured absorptions are calculated after 
subtraction of the substrate blank value.
15.If the value of the sample is higher than that of cut-off value, there is 
a positive result.
ANNXUREE III
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